Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?

Coşkun B. N., Yagiz B., Corabay S. G., Pehlivan Y., Dalkılıç H. E.

EUROPEAN JOURNAL OF RHEUMATOLOGY, cilt.9, sa.2, ss.68-74, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5152/eurjrheum.2022.21099
  • Dergi Adı: EUROPEAN JOURNAL OF RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.68-74
  • Anahtar Kelimeler: Ankylosing spondylitis, anti-TNF drugs, chronic kidney disease, efficacy, safe, STAGE RENAL-DISEASE, SECONDARY AMYLOIDOSIS, RHEUMATOID-ARTHRITIS, RISK, ETANERCEPT, PREVALENCE, SPONDYLOARTHRITIS, METHOTREXATE, ADALIMUMAB, INFECTIONS
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Objective: This study aims to examine the efficacy and safety of the antitumor necrosis factor (TNF) drugs in ankylosing spondylitis (AS) patients with chronic kidney disease.